A Phase 3 interventional study of Chiglitazar and Placebo in Type 2 Diabetes, sponsored by Chipscreen Biosciences, Ltd.. Completed at 26 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-10-25.
Sponsored by Chipscreen Biosciences, Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.
Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 158th largest by enrollment of the 767 interventional ones that give a count, is one of 32 that started in 2014, is one of 207 in phase 3, and was the 192nd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in China, United States, Brazil and 7 more countries
Ages 18+
BrightGene Bio-Medical Technology Co., Ltd. · Sites in China
Ages 18–75
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–75
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
909 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 142 · Phase 2 90 · Phase 3 216 · Phase 4 155
First in 1998; this study’s year is marked. 32 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 535 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 199 across the 767 interventional studies, 593 across the 141 observational. Of the 518 that completed or were terminated, 123 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
448 of 909 have an industry lead sponsor. The 10 most frequent:
Chipscreen Biosciences, Ltd. is the lead sponsor of 42 studies on the registry; 11 are open to participants now.
Chipscreen Biosciences, Ltd. has 7 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
54 of the studies in Diabetes Mellitus, Type 2 with a site in China that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07060456Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin | 2027-02 |
| NCT07082114Phase 3Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus | 2027-02-16 |
| NCT07156500Phase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone | 2027-03-30 |
| NCT07156539Phase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.A Phase 3 Study of HS-20094 in Patients With T2DM | 2027-03-30 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Add all 54 to your calendar (.ics) → With an account.
Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare with placebo.
The efficacy and safety will be compared between Chiglitazar and placebo after treatment of 24 weeks. The long term efficacy and safety of Chiglitazar will be evaluated after 52 weeks treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients administrate Chiglitazar 32mg once daily for 52 weeks
Drug: Chiglitazar
Patients administrate Chiglitazar 48mg once daily for 52 weeks
Drug: Chiglitazar
Patients administrate placebo for 24 weeks.From week 25 to 52, patients are randomly switched to Arm 1 and Arm 2, and receive the treatment accordingly.
Drug: Chiglitazar · Drug: Placebo
Take orally
Also known as: CS038
Take orally
Also known as: Plb
Change in HbA1c from baseline after 24 weeks of treatment
The change of HbA1c at week 24 from baseline
Time frame: 24 weeks
Change in HbA1c from baseline for patients with a baseline HbA1c >=8.5%
The change of HbA1c at week 24 from baseline for patients with a HbA1c \>=8.5% at baseline
Time frame: 24 weeks
Change in HbA1c from baseline in patients with a baseline HbA1c < 8.5%
The change of HbA1c at week 24 from baseline for patients with a HbA1c \< 8.5% at baseline
Time frame: 24 weeks
Change in HbA1c from baseline
The change of HbA1c at week 12 from baseline
Time frame: 12 weeks
Change in HbA1c from baseline
The change of HbA1c at week 52 from baseline
Time frame: 52 weeks
Percentage of patients that attained target HbA1c <7.0%
Percentage of patients whose HbA1c at week 24 are \< 7.0%
Time frame: 24 weeks
Percentage of patients whose HbA1c lowered by at least 0.5%
Percentage of patients whose change of HbA1c at week 24 from baseline are \>= 0.5%
Time frame: 24 weeks
Change in fasting plasma glucose from baseline
The change of fasting plasma glucose at week 12 and 24 from baseline
Time frame: 12,24 and 52 weeks
Change in 2-h postprandial glucose (2hPPG) from baseline
The change of 2-h postprandial glucose (2hPPG) at week 12, 24 and 52 from baseline
Time frame: 12, 24 and 52 weeks
Change in total cholesterol (TC) from baseline
The change of total cholesterol (TC) at week 12, 24 and 52 from baseline
Time frame: 12, 24 and 52 weeks
Change in triglyceride from baseline
The change of triglyceride at week 12, 24 and 52 from baseline
Time frame: 12,24 and 52 weeks
Change in high density lipoprotein cholesterol (HDL-C)from baseline
The change of high density lipoprotein cholesterol (HDL-C) at week week 12, 24 and 52 from baseline
Time frame: 12, 24 and 52 weeks
Change in low density proprotein cholesterol (LDL-C) from baseline
The change of low density lipoprotein cholesterol (LDL-C) at week 12, 24 and 52 from baseline
Time frame: 12, 24 and 52 weeks
Change in free fatty acid (FFA) from baseline
The change of free fatty acid (FFA) at week 12, 24 and 52 from baseline
Time frame: 12, 24 and 52 weeks
Change in fasting plasma insulin from baseline
The change of fasting plasma insulin at week 12, 24 and 52 from baseline
Time frame: 12, 24 and 52 weeks
Insulin sensitivity assessed by the homeostatic model assessment (HOMA) at 12,24 and 52 weeks, compared with that of baseline
The change of insulin sensitivity at week 12, 24 and 52 from baseline
Time frame: 12, 24 and 52 weeks
Change in blood pressure from baseline
The change of blood pressure at week 24 from baseline
Time frame: 24 weeks
Percentage of patients who use rescue therapy
The percentage of patients who use rescue therapy during the 52 weeks of treatment
Time frame: 52 weeks
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Jun 2014, a primary completion of Nov 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chiglitazar
Chipscreen Biosciences, Ltd. →